Search

Your search keyword '"Stamatoullas A"' showing total 1,449 results
Start Over Author "Stamatoullas A"
1,449 results on '"Stamatoullas A"'

1. Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials

Author

Juul, Sidsel J., Rossetti, Sára, Aleman, Berthe M. P., van Leeuwen, Flora E., van der Kaaij, Marleen A. E., Giusti, Francesco, Meijnders, Paul, Raemaekers, John M. M., Kluin-Nelemans, Hanneke C., Spina, Michele, Krzisch, Daphne, Bigenwald, Camille, Stamatoullas, Aspasia, André, Marc, Plattel, Wouter J., Hutchings, Martin, and Maraldo, Maja V.

Published
2024
Full Text
View/download PDF

2. Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials

Author

Juul, Sidsel J., Rossetti, Sára, Kicinski, Michal, van der Kaaij, Marleen A. E., Giusti, Francesco, Meijnders, Paul, Aleman, Berthe M. P., Raemaekers, John M. M., Kluin-Nelemans, Hanneke C., Spina, Michele, Fermé, Christophe, Renaud, Loïc, Casasnovas, Olivier, Stamatoullas, Aspasia, André, Marc, Le Bras, Fabien, Plattel, Wouter J., Henry-Amar, Michel, Hutchings, Martin, and Maraldo, Maja V.

Published
2024
Full Text
View/download PDF

3. Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia

Author

Chevallier, Patrice, Leguay, Thibaut, Delord, Marc, Salek, Cyril, Kim, Rathana, Huguet, Françoise, Hicheri, Yosr, Wartiovaara-Kautto, Ulla, Raffoux, Emmanuel, Cluzeau, Thomas, Balsat, Marie, Roth-Guepin, Gabrielle, Tavernier, Emmanuelle, Lepretre, Stephane, Bilger, Karin, Bergugnat, Hugo, Berceanu, Ana, Alexis, Magda, Doubek, Michael, Brissot, Eolia, Hunault-Berger, Mathilde, Lebon, Delphine, Turlure, Pascal, Chantepie, Sylvain, Belhabri, Amine, Wickenhauser, Stefan, Bastie, Jean-Noel, Cacheux, Victoria, Himberlin, Chantal, Banos, Anne, Gardin, Claude, Bonnet, Sarah, Plantier, Isabelle, Pica, Gian Matteo, Escoffre-Barbe, Martine, Boissel, Nicolas, Dombret, Herve, Clappier, Emmanuelle, Rousselot, Philippe, Lebon, Delphine, Charbonnier, Amandine, Assouan, Deborah, Hubert, Amandine, Quint, Marine, Kossi, Fulvia Guenbem, Deruche, Elodie, Hunault, Mathilde, Marie, Céline, Banos, Anne, Robin, Jean-Baptiste, Gay, Julie, Capdupuy, Claudie, Labarrere, Sévérine, Vincent, Edith, Simonet-Boissard, Marion, BeRceanu, Ana, Larosa, Fabrice, Desbrosses, Yohan, Boiteux, Guillaume, Dufour, Vinciane, Tissot, Elise, Braun, Thorsten, Gardin, Pr Claude, Vidal, Valérie, Edouart, Geoffrey, Chantepie, Sylvain, Vilque, Jean-Pierre, Johnson Ansah, Hyacinthe, Lebouvier, Angélique, Zapalovicz, Marie Charlotte, Renault, Léa, Gian Matteo, Pica, Courouau, Alix, Prieur, Fabienne, Dupre, Charlene, Cacheux, Victoria, De Renzis, Benoit, Chaleteix, Carine, Fayard, Amandine, Roy, Gwendoline, Bastie, Jean-Noël, Caillot, Denis, Devaux, Laetitia, Chevallier, Patrice, Lebourgeois, Amandine, Bonnet, Antoine, Peterlin, Pierre, Lok, Anne, Guilllaume, Thierry, Fontaine, Alexis Morice, Turlure, Pascal, Touati, Mohamed, Kennel, Céline, Dmytruck, Natalya, Abraham, Julie, Jaccard, Arnaud, Remenieras, Liliane, Girault, Stéphane, Gourin, Marie Pierre, Penot, Amélie, Moreau, Stéphane, Philipon, Céline, Roche, Delphine, Belhabri, Amine, Gilis, Lila, Virelizier, Nicolas, Michalet, Anne-Sophie, Monfray, Jérémy, Balsat, Marie, Thomas, Xavier, Praire, Aline, Guepin, Gabrielle Roth, Bonmati, Caroline, Moulin, Charline, Jacquet, Caroline, Carpodomi, Anne, Bouillet, Hélène, Carpentier, Odile, Montero, Mélanie, Pires, Aude, Gastaud, Lauris, Gama, Anastasia, Coelle, Céline, Karmout, Sonia, Cluzeau, Thomas, Loschi, Michael, Lechardeur, Jessica, Chokri, Hatroubi, Broussot, Loic, Wickenhauser, Stefan, Waulthier, Agathe, Jourdan, Eric, Scherman, Elodie, Umuhire, Diane, Damiano, Maria Alessandra, Hicheri, Yors, Saillard, Colombe, DʼIncan, Evelyne, Hospital, Marie-Anne, LʼAttention, Jean Laurent, Rabah, Mme Nassima, Cesari, Laura Castillo, Gehlkopf, Eve, Vincent, Laure, Navarro, Robert, Quittet, Philippe, Fegueux, Nathalie, Ceballos, Patrice, Marin, Fanny Baguet, Sabadash, Véra, Alexis, Magda, Ochmann, Marlène, Laboure, Nina Akakelyan, Bembrahmi, Omar, Michel, Olivier, Ouahrawi, Brahim, Brissot, Eolia, Legrand, Olivier, Vekhoff, Anne, Isnard, Françoise, Sa, Sara E., Dombret, Hervé, Raffoux, Emmanuel, Lenguine, Etienne, Rabian, Florence, Lebras, Karine Celli, Fauvaux, Catherine, Leguay, Thibaut, Gros, François-Xavier, Debus, Cazaubiel, Titouan, Melot, Cyril, Dematteis, Valentin, Messina, Antonella, Himberlin, Chantal, Le, Quoc-Hung, Maggi, Lucia, Barre, Martine Escoffre, Moignet, Aline, De Guibert, Sophie, Bernard, Marc, Decaux, Olivier, de la Chapelle, Thierry Lamy, Nimubona, Stanislas, Kadende, Mme Erica, Flavigny, Aloyse, Plantier, Isabelle, Detourmignies, Laurence, Wemeau, Mathieu, Dervite, Isabelle, Dernivoix, Kathy, Camille, Mme, Denizart, Ingrid, Lepretre, Stéphane, Stamatoullas-Bastard, Aspasia, Fontoura, Marie-Laure, Jardin, Fabrice, Menard, Anne-Lise, Camus, Vincent, Lanic, Helene, Contentin, Nathalie, Cardinael, Nathalie, Lemasle-Hue, Emilie, Alani, Mustafa, Lebreton, Pierre, Atia, Youcef, Bilger, Karin, Ledoux, Marie-Pierre, Sonntag, Cécile, Collin, Camille, Tavernier, Emmanuelle, Guyotat, Denis, Soglu, Gilbert, Le Jeune, Caroline, Cornillon, Jérôme, Durieux, Coralie, Lavoué, Céline, Miler, Dorante, Huguet, Françoise, Tavitian, Suzanne, Soldan, Justine, Rousselot, Philippe, Rigaudeau, Sophie, Philippe, Laure, Lambert, Juliette, Besson, Caroline, Cabannes, Aurélie, Longval, Thomas, Taksin, Anne-Laure, Bah, Mariama, BeulayGue, Anaïs, Doubek, Michael, Folber, Frantisek, Hrabovsky, Stepan, Brzonova, Jana, Vejsadova, Hana, Salek, Cyril, Novotova, Elena, Mertova, Jolana, Brzonova, Jana, Vejsadova, Hana, Wartiovaara-Kautto, Ulla, Salonen, Minna, and Vaalas, Saara

Published
2024
Full Text
View/download PDF

4. Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B-cell lymphoma: results of a multicentric prospective cohort study

Author

Pénichoux, Juliette, Lanic, Hélène, Thill, Caroline, Ménard, Anne-Lise, Camus, Vincent, Stamatoullas, Aspasia, Lemasle, Emilie, Leprêtre, Stéphane, Lenain, Pascal, Contentin, Nathalie, Kraut-Tauzia, Jerôme, Fruchart, Christophe, Kammoun, Leila, Damaj, Gandhi, Farge, Agathe, Delette, Caroline, Modzelewski, Romain, Vaudaux, Sandrine, Pépin, Louis-Ferdinand, Tilly, Hervé, and Jardin, Fabrice

Published
2023
Full Text
View/download PDF

5. Correction to: Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B‑cell lymphoma: results of a multicentric prospective cohort study

Author

Pénichoux, Juliette, Lanic, Hélène, Thill, Caroline, Ménard, Anne-Lise, Camus, Vincent, Stamatoullas, Aspasia, Lemasle, Emilie, Leprêtre, Stéphane, Lenain, Pascal, Contentin, Nathalie, Kraut-Tauzia, Jérôme, Fruchart, Christophe, Kammoun, Leïla, Damaj, Gandhi, Farge, Agathe, Delette, Caroline, Modzelewski, Romain, Vaudaux, Sandrine, Pépin, Louis-Ferdinand, Tilly, Hervé, and Jardin, Fabrice

Published
2024
Full Text
View/download PDF

6. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable – a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Author

Drozd-Sokolowska, Joanna, Gras, Luuk, Zinger, Nienke, Zahrani, Mohsen Al, Passweg, Jakob, Byrne, Jenny, Ho, Aloysius, Huang, Xiao-jun, Kröger, Nicolaus, Mayer, Jiri, Russo, Domenico, De Becker, Ann, Tbakhi, Abdelghani, Stamatoullas, Aspasia, Valerius, Thomas, Hayden, Patrick, McLornan, Donal P., Onida, Francesco, Scheid, Christof, Robin, Marie, and Yakoub-Agha, Ibrahim

Published
2023
Full Text
View/download PDF

7. High prevalence of pre-existing sarcopenia in critically ill patients with hematologic malignancies admitted to the intensive care unit for sepsis or septic shock

Author

Herault, Antoine, Lévêque, Emilie, Draye-Carbonnier, Simon, Decazes, Pierre, Zduniak, Alexandra, Modzelewski, Romain, Libraire, Julie, Achamrah, Najate, Ménard, Anne-Lise, Lenain, Pascal, Contentin, Nathalie, Grall, Maximilien, Leprêtre, Stéphane, Lemasle, Emilie, Lanic, Hélène, Alani, Mustafa, Stamatoullas-Bastard, Aspasia, Tilly, Hervé, Jardin, Fabrice, Tamion, Fabienne, and Camus, Vincent

Published
2023
Full Text
View/download PDF

8. PB2670: EQOL-MDS TRIAL: PATIENT-REPORTED OUTCOMES IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA.

Author

Esther Oliva, Giuseppe Iannì, Marta Riva, Pasquale Niscola, Valeria Santini, Massimo Breccia, Valentina Gaidano, Antonella Poloni, Andrea Patriarca, Elena Crisà, Isabella Capodanno, Prassede Salutari, Gianluigi Reda, Grazia Sanpaolo, Dario Ferrero, Attilio Guarini, Giovanni Tripepi, Andrea Castelli, Bruno Fattizzo, Germana Beltrami, Monica Bocchia, Alfredo Molteni, Pierre Fenaux, Ulrich Germing, Alessandra Ricco, Giuseppe A. Palumbo, Stefana Impera, Nicola DI Renzo, Francesco Buccisano, Aspasia Stamatoullas, Anna Marina Liberati, Anna Candoni, Ilaria Maria Delfino, Patrizia Cufari, Lorenzo Rizzo, and Roberto Latagliata

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

9. A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome.

Author

Bondu, Sabrina, Alary, Anne-Sophie, Lefèvre, Carine, Houy, Alexandre, Jung, Grace, Lefebvre, Thibaud, Rombaut, David, Boussaid, Ismael, Bousta, Abderrahmane, Guillonneau, François, Perrier, Prunelle, Alsafadi, Samar, Wassef, Michel, Margueron, Raphaël, Rousseau, Alice, Droin, Nathalie, Cagnard, Nicolas, Kaltenbach, Sophie, Winter, Susann, Kubasch, Anne-Sophie, Bouscary, Didier, Santini, Valeria, Toma, Andrea, Hunault, Mathilde, Stamatoullas, Aspasia, Gyan, Emmanuel, Cluzeau, Thomas, Platzbecker, Uwe, Adès, Lionel, Puy, Hervé, Stern, Marc-Henri, Karim, Zoubida, Mayeux, Patrick, Nemeth, Elizabeta, Park, Sophie, Ganz, Tomas, Kautz, Léon, Kosmider, Olivier, and Fontenay, Michaëla

Subjects
Alternative Splicing, Amino Acid Sequence, Animals, Blood Transfusion, Cell Line, Cell Lineage, Cell Survival, Clone Cells, Erythroid Cells, Hepcidins, Homeostasis, Humans, Iron, Lenalidomide, Mice, Mutation, Myelodysplastic Syndromes, Peptide Hormones, Phosphoproteins, Protein Biosynthesis, RNA Splice Sites, RNA Splicing Factors, RNA, Messenger, Up-Regulation
Abstract

Myelodysplastic syndromes (MDS) with ring sideroblasts are hematopoietic stem cell disorders with erythroid dysplasia and mutations in the SF3B1 splicing factor gene. Patients with MDS with SF3B1 mutations often accumulate excessive tissue iron, even in the absence of transfusions, but the mechanisms that are responsible for their parenchymal iron overload are unknown. Body iron content, tissue distribution, and the supply of iron for erythropoiesis are controlled by the hormone hepcidin, which is regulated by erythroblasts through secretion of the erythroid hormone erythroferrone (ERFE). Here, we identified an alternative ERFE transcript in patients with MDS with the SF3B1 mutation. Induction of this ERFE transcript in primary SF3B1-mutated bone marrow erythroblasts generated a variant protein that maintained the capacity to suppress hepcidin transcription. Plasma concentrations of ERFE were higher in patients with MDS with an SF3B1 gene mutation than in patients with SF3B1 wild-type MDS. Thus, hepcidin suppression by a variant ERFE is likely responsible for the increased iron loading in patients with SF3B1-mutated MDS, suggesting that ERFE could be targeted to prevent iron-mediated toxicity. The expression of the variant ERFE transcript that was restricted to SF3B1-mutated erythroblasts decreased in lenalidomide-responsive anemic patients, identifying variant ERFE as a specific biomarker of clonal erythropoiesis.

Published
2019

10. Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T‐cell lymphoma: A case report

Author

Vincent Camus, Pascaline Etancelin, Fanny Drieux, Elena‐Liana Veresezan, Jean‐Michel Picquenot, Dominique Penther, Mathieu Viennot, Philippe Ruminy, Nathalie Contentin, Emilie Lemasle, Stéphane Leprêtre, Sydney Dubois, Juliette Penichoux, Aspasia Stamatoullas, Alexandra Zduniak, Hélène Lanic, and Fabrice Jardin

Subjects
allogenic stem cell transplantation, belinostat, complete response, HDAC inhibitor, nTFHL‐AI, PTCL, Medicine, Medicine (General), R5-920
Abstract

Key Clinical Message This case report highlights the potential of belinostat for the treatment of relapsed/refractory peripheral T‐cell lymphomas, for which effective therapies are still scarce. Abstract Peripheral T‐cell lymphomas have an aggressive disease course associated with poor outcomes. We report a young patient with highly pretreated relapsed/refractory nodal follicular helper T‐cell lymphoma (angioimmunoblastic‐type [nTFHL‐AI]), who successfully received an allogeneic stem cell transplantation following belinostat therapy. The complete hematologic response achieved has lasted more than 2 years.

Published
2023
Full Text
View/download PDF

11. Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma

Author

Pierre Pinochet, Edgar Texte, Aspasia Stamatoullas-Bastard, Pierre Vera, Sorina-Dana Mihailescu, and Stéphanie Becker

Subjects
Medicine, Science
Abstract

Abstract Our aim was to evaluate the prognostic value of initial total metabolic tumour volume (TMTV) in a population of patients with advanced-stage Hodgkin’s lymphoma (HL). We retrospectively included 179 patients with stage IIb-III-IV Hodgkin’s disease who received BEACOPP or ABVD as the first-line treatment. The initial TMTV was determined using a semi-automatic method for each patient. We analysed its prognostic value in terms of 5-year progression-free survival (PFS), overall survival, and positron emission tomography (PET) response after two courses of chemotherapy. Considering all the treatments and using a threshold of 217 cm3, TMTV was predictive of 5-year PFS and PET response after two courses of chemotherapy. In multivariable analysis involving TMTV, IPI score, and the first treatment received, TMTV remained a baseline prognostic factor for 5-year PFS. In the subgroup of patients treated with BEACOPP with a threshold of 331 cm3, TMTV was predictive of PET response, but not 5-year PFS (p = 0.087). The combined analysis of TMTV and PET response enabled the individualisation of a subgroup of patients (low TMTV and complete response on PET) with a very low risk of recurrence. Baseline TMTV appears to be a useful independent prognostic factor for predicting relapse in advanced-stage HL in ABVD subgroup, with a tendency of survival curves separation in BEACOPP subgroup.

Published
2021
Full Text
View/download PDF

12. Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?

Author

Selma Addou, Clémentine Sarkozy, Julien Lazarovici, Stéphane Champiat, Aspasia Stamatoullas, Fabrice Jardin, Vincent Ribrag, Aurélien Marabelle, and Jean-Marie Michot

Subjects
hodgkin lymphoma, virotherapy, oncolytic viruses, epstein-barr virus, Immunologic diseases. Allergy, RC581-607, Therapeutics. Pharmacology, RM1-950
Abstract

Classical Hodgkin lymphoma is a neoplastic hematological disease. Standard first-line therapy, including chemotherapy and radiotherapy, is curative in >85% of early-stage patients, with a 5-year survival rate of >95%. However, approximately 15% of patients have hard-to-treat lymphoma with poor outcomes, and new treatment strategies are needed for these young adults. There are several well-documented cases in the medical literature on hematologic cancer remission following natural human viral infections. Therefore, hoping to reproduce these spontaneous tumor regressions, researchers have been investigating various viruses with oncolytic properties. There is a high rationale for using virotherapy in the treatment of Hodgkin lymphoma, in which tumor cells are often infected with the Epstein-Barr virus. Modern viral technologies and current knowledge about the relationship between viruses and cancer could accelerate the discovery of effective viral oncolytic therapies. This article reviews the use of oncolytic viruses as innovative therapies for treating Hodgkin lymphoma.

Published
2021
Full Text
View/download PDF

13. Successful treatment of severe post hematopoietic stem cell transplantation bronchiolitis obliterans syndrome with lung transplantation in a patient with multi‐organ chronic graft‐versus‐host disease

Author

Juliette Pénichoux, Florian Bouclet, Mustafa Alani, Nathalie Contentin, Anne‐Lise Ménard, Stéphane Leprêtre, Pascal Lenain, Aspasia Stamatoullas, Elodie Lhuillier, Hélène Lanic, Emilie Lemasle, Sydney Dubois, Jean‐Henri Bourhis, Hervé Mal, Fabrice Jardin, and Vincent Camus

Subjects
allogeneic hematopoietic stem cell transplantation, bronchiolitis obliterans syndrome, graft‐versus‐host disease, Medicine, Medicine (General), R5-920
Abstract

Abstract Allogeneic stem cell transplant and chronic graft‐versus‐host disease may lead to severe non‐infectious pulmonary disease in 6% of patients at 5 years. We report the case of a young patient with acute myeloid leukemia who successfully received bilateral lung transplantation for severe bronchiolitis obliterans syndrome.

Published
2022
Full Text
View/download PDF

15. Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia.

Author

Marchand, Tony, Pastoret, Cédric, Damaj, Gandhi, Lebouvier, Angélique, Herbaux, Charles, Moignet, Aline, Pavlosky, Miguel, Pavlosky, Astrid, Blouet, Anaise, Eloit, Martin, Launay, Vincent, Lebreton, Pierre, Stamatoullas, Aspasia, Nilsson, Christer, Ochmann, Marlène, Prola, Juliette, and Lamy, Thierry

Subjects
CYTOTOXIC T cells, LYMPHOCYTIC leukemia, IMMUNOSUPPRESSIVE agents, LYMPHOPROLIFERATIVE disorders, OVERALL survival
Abstract

Summary: Large granular lymphocytic (LGL) leukaemia is a rare chronic lymphoproliferative disorder characterized by an expansion of cytotoxic T or NK cells. Despite a usually indolent evolution, most patients will require a treatment over the course of the disease because of cytopenia or symptomatic associated autoimmune disorders. First‐line treatment is based on immunosuppressive agents, namely cyclophosphamide, methotrexate and ciclosporin. However, relapses are frequent, and there is no consensus on the management of relapsed/refractory patients. The implication of the JAK/STAT pathway in the pathogenesis of this disease has prompted our group to propose treatment with ruxolitinib. A series of 21 patients who received this regimen is reported here. Ten patients (47.6%) were refractory to the three main immunosuppressive drugs at the time of ruxolitinib initiation. Ruxolitinib yielded an overall response rate of 86% (n = 18/21), including 3 complete responses and 15 partial responses. With a median follow‐up of 9 months, the median response duration was 4 months. One‐year event‐free survival and 1‐year overall survival were 57% and 83% respectively. Mild side effects were observed. Biological parameters, notably neutropenia and anaemia, improved significantly, and complete molecular responses were evidenced. This study supports ruxolitinib as a valid option for the treatment of relapsed/refractory LGL leukaemia. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline

Author

Cédric Rossi, Marc André, Jehan Dupuis, Franck Morschhauser, Bertrand Joly, Julien Lazarovici, Hervé Ghesquières, Aspasia Stamatoullas, Emmanuelle Nicolas-Virelizier, Pierre Feugier, Anne-Claire Gac, Hannah Moatti, Luc-Matthieu Fornecker, Bénédicte Deau, Clémentine Joubert, Catherine Fortpied, John Raemaekers, Massimo Federico, Salim Kanoun, Michel Meignan, Alexandra Traverse-Glehen, Anne-Ségolène Cottereau, and René-Olivier Casasnova

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Stage IIB Hodgkin lymphoma (HL) patients, with a mediastinum-to-thorax (M/T) ratio of ≥0.33 or extranodal localization have a poor prognosis and are treated either as limited or advanced stage. We compared these two approaches in patients included in two randomized phase III trials enrolling previously untreated early (H10) or advanced stage HL (AHL2011). We included HL patients with Ann-Arbor stage IIB with M/T ≥0.33 or extranodal involvement enrolled in the H10 or AHL2011 trials with available positron emission tomography at baseline (PET0) and after two cycles of chemotherapy (PET2). Baseline total metabolic tumor volume (TMTV) was calculated using the 41% SUVmax method. PET2 response assessment used the Deauville score. One hundred and fourty-eight patients were eligible, including 83 enrolled in the AHL2011 trial and 65 in the H10 trial. The median TMTV value was 155.5 mL (range, 8.3-782.9 mL), 165.6 mL in AHL2011 and 147 mL in H10. PET2 positivity rates were 16.9% (n=14) and 9.2% (n=6) in AHL2011 and H10 patients, respectively. With a median follow-up of 4.1 years (95% confidence interval [CI]: 3.9-4.4), overall 4-year PFS was 88.0%, 87.0% in AHL2011 and 89.2% in H10. In univariate and mutivariate analyses, baseline TMTV and PET2 response influenced significantly progression-free survival (hazard ratio [HR]=4.94, HR=3.49 respectively). Notably, among the 16 patients who relapsed, 13 (81%) had a baseline TMTV baseline ≥155 mL. Upfront ABVD plus radiation therapy or upfront escBEACOPP without radiotherapy provide similar patient’s outcome in high-risk stage IIB HL. TMTV is useful to stratify these patients at baseline.

Published
2022
Full Text
View/download PDF

18. Multiple cutaneous ulcers revealing a primary cutaneous Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma

Author

Billal Tedbirt, Sydney Dubois, Lucie Cellier, Priscille Carvalho, Aspasia Stamatoullas, Philippe Courville, Aurélie Deschamps‐Huvier, Pascaline Etancelin, Anne Deniel, Hervé Tilly, Fabrice Jardin, Pascal Joly, and Vincent Camus

Subjects
cutaneous lymphoma, cutaneous ulcers, Epstein‐Barr virus, Medicine, Medicine (General), R5-920
Abstract

Abstract Primary cutaneous EBV‐positive diffuse large B‐cell lymphoma is an exceptional and aggressive neoplasia with a poorer prognosis than other cutaneous lymphoma. Our observation points out the rarity of the presentation and the dismal clinical course.

Published
2020
Full Text
View/download PDF

19. Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study

Author

Amira Marouf, Anne Segolene Cottereau, Salim Kanoun, Paul Deschamps, Michel Meignan, Patricia Franchi, David Sibon, Clara Antoine, Thomas Gastinne, Cecile Borel, Mohammad Hammoud, Guillaume Sicard, Romane Gille, Doriane Cavalieri, Aspasia Stamatoullas, Lauriane Filliatre-Clement, Julien Lazarovici, Adrien Chauchet, Luc-Matthieu Fornecker, Sandy Amorin, Mathieu Rocquet, Nicole Raus, Barbara Burroni, Marie Therese Rubio, Didier Bouscary, Philippe Quittet, Rene Olivier Casasnovas, Pauline Brice, Herve Ghesquieres, Jérôme Tamburini, and Benedicte Deau

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2021
Full Text
View/download PDF

20. Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas

Author

Sophie Candon, Veronique Lemee, Emilie Leveque, Pascaline Etancelin, Cedric Paquin, Marion Carette, Nathalie Contentin, Victor Bobee, Mustafa Alani, Nathalie Cardinael, Stephane Lepretre, Vincent Camus, Florian Bouclet, Edwige Boulet, Anne-Lise Menard, Helene Lanic, Aspasia Stamatoullas, Emilie Lemasle, Louis-Ferdinand Pepin, Doriane Richard, Sydney Dubois, Herve Tilly, Alain Dalleac, Jean-Christophe Plantier, Manuel Etienne, and Fabrice Jardin

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2021
Full Text
View/download PDF

23. Correction to: Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B‑cell lymphoma: results of a multicentric prospective cohort study

Author

Pénichoux, Juliette, primary, Lanic, Hélène, additional, Thill, Caroline, additional, Ménard, Anne-Lise, additional, Camus, Vincent, additional, Stamatoullas, Aspasia, additional, Lemasle, Emilie, additional, Leprêtre, Stéphane, additional, Lenain, Pascal, additional, Contentin, Nathalie, additional, Kraut-Tauzia, Jérôme, additional, Fruchart, Christophe, additional, Kammoun, Leïla, additional, Damaj, Gandhi, additional, Farge, Agathe, additional, Delette, Caroline, additional, Modzelewski, Romain, additional, Vaudaux, Sandrine, additional, Pépin, Louis-Ferdinand, additional, Tilly, Hervé, additional, and Jardin, Fabrice, additional

Published
2023
Full Text
View/download PDF

24. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)

Author

Oliva, Esther Natalie, primary, Riva, Marta, additional, Niscola, Pasquale, additional, Santini, Valeria, additional, Breccia, Massimo, additional, Giai, Valentina, additional, Poloni, Antonella, additional, Patriarca, Andrea, additional, Crisà, Elena, additional, Capodanno, Isabella, additional, Salutari, Prassede, additional, Reda, Gianluigi, additional, Cascavilla, Nicola, additional, Ferrero, Dario, additional, Guarini, Attilio, additional, Tripepi, Giovanni, additional, Iannì, Giuseppe, additional, Russo, Emilio, additional, Castelli, Andrea, additional, Fattizzo, Bruno, additional, Beltrami, Germana, additional, Bocchia, Monica, additional, Molteni, Alfredo, additional, Fenaux, Pierre, additional, Germing, Ulrich, additional, Ricco, Alessandra, additional, Palumbo, Giuseppe A., additional, Impera, Stefana, additional, Di Renzo, Nicola, additional, Rivellini, Flavia, additional, Buccisano, Francesco, additional, Stamatoullas-Bastard, Aspasia, additional, Liberati, Anna Marina, additional, Candoni, Anna, additional, Delfino, Ilaria Maria, additional, Arcadi, Maria Teresa, additional, Cufari, Patrizia, additional, Rizzo, Lorenzo, additional, Bova, Irene, additional, D'Errigo, Maria Grazia, additional, Zini, Gina, additional, and Latagliata, Roberto, additional

Published
2023
Full Text
View/download PDF

25. Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study

Author

Raphaël Busson, Marleen van der Kaaij, Nicolas Mounier, Berthe M. P. Aleman, Catherine Thiéblemont, Aspasia Stamatoullas, Vincent Ribrag, Hervé Tilly, Corinne Haioun, René-Olivier Casasnovas, Hanneke C. Kluin-Nelemans, and Michel Henry-Amar

Subjects
Hodgkin lymphoma, Non-Hodgkin lymphomas, Long-term survivors, Fatigue, Cross-sectional study, Computer applications to medicine. Medical informatics, R858-859.7
Abstract

Abstract Background Long-term lymphoma survivors often complain of persistent fatigue that remains unexplained. While largely reported in Hodgkin lymphoma (HL), long-term fatigue is poorly documented in non-Hodgkin lymphomas (NHL). Data collected in two cohort studies were used to illustrate the fatigue level changes with time in the two populations. Methods Two cross-sectional studies were conducted in 2009–2010 (HL) and in 2015 (NHL) in survivors enrolled in European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group and Lymphoma Study Association (LYSA) trials. The same protocol and questionnaires were used in both studies including the Multidimensional Fatigue Inventory (MFI) tool to assess fatigue and a checklist of health disorders. Multivariate linear regression models were used in the two populations separately to assess the influence of time since diagnosis and primary treatment, age, gender, education level, cohabitation status, obesity and health disorders on fatigue level changes. Fatigue level changes were compared to general population data. Results Overall, data of 2023 HL and 1619 NHL survivors with fatigue assessment available (99 and 97% of cases, respectively) were analyzed. Crude levels of fatigue were similar in the two populations. Individuals who reported health disorders (61% of HL and 64% of NHL) displayed higher levels of fatigue than those who did not (P

Published
2019
Full Text
View/download PDF

26. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network

Author

Raphael Itzykson, Valeria Santini, Sylvain Thepot, Lionel Ades, Cendrine Chaffaut, Aristoteles Giagounidis, Margot Morabito, Nathalie Droin, Michael Lübbert, Rosa Sapena, Stanislas Nimubona, Jean Goasguen, Eric Wattel, Gina Zini, Jose Miguel Torregrosa Diaz, Ulrich Germing, Anna Maria Pelizzari, Sophie Park, Nadja Jaekel, Georgia Metzgeroth, Francesco Onida, Robert Navarro, Andrea Patriarca, Aspasia Stamatoullas, Katharina Götze, Martin Puttrich, Sandra Mossuto, Eric Solary, Silke Gloaguen, Sylvie Chevret, Fatiha Chermat, Uwe Platzbecker, and Pierre Fenaux

Subjects
Cancer Research, Oncology
Abstract

PURPOSE Hydroxyurea (HY) is a reference treatment of advanced myeloproliferative neoplasms. We conducted a randomized phase III trial comparing decitabine (DAC) and HY in advanced myeloproliferative chronic myelomonocytic leukemias (CMML). PATIENTS AND METHODS Newly diagnosed myeloproliferative CMML patients with advanced disease were randomly assigned 1:1 to intravenous DAC (20 mg/m2/d days 1-5) or HY (1-4 g/d) in 28-day cycles. The primary end point was event-free survival (EFS), events being death and acute myelomonocytic leukemia (AML) transformation or progression. RESULTS One-hundred seventy patients received DAC (n = 84) or HY (n = 86). Median age was 72 and 74 years, and median WBC count 32.5 × 109/L and 31.2 × 109/L in the DAC and HY arms, respectively. Thirty-three percent of DAC and 31% of HY patients had CMML-2. Patients received a median of five DAC and six HY cycles. With a median follow-up of 17.5 months, median EFS was 12.1 months in the DAC arm and 10.3 months in the HY arm (hazard ratio [HR], 0.83; 95% CI, 0.59 to 1.16; P = .27). There was no significant interaction between treatment effect and blast or platelet count, anemia, CMML Prognostic Scoring System, Groupe Francophone des Myelodysplasies, or CMML Prognostic Scoring System–mol risk. Fifty-three (63%) DAC patients achieved a response compared with 30 (35%) HY patients ( P = .0004). Median duration of response was similar in both arms (DAC, 16.3 months; HY, 17.4 months; P = .90). Median overall survival was 18.4 months in the DAC arm and 21.9 months in the HY arm ( P = .67). Compared with HY, DAC significantly reduced the risk of CMML progression or transformation to acute myelomonocytic leukemia (cause-specific HR, 0.62; 95% CI, 0.41 to 0.94; P = .005) at the expense of death without progression or transformation (cause-specific HR, 1.55; 95% CI, 0.82 to 2.9; P = .04). CONCLUSION Compared with HY, frontline treatment with DAC did not improve EFS in patients with advanced myeloproliferative CMML (ClinicalTrials.gov identifier: NCT02214407 ).

Published
2023
Full Text
View/download PDF

27. Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial

Author

Thomas, José, Fermé, Christophe, Noordijk, Evert M., Morschhauser, Franck, Girinsky, Théodore, Gaillard, Isabelle, Lugtenburg, Pieternella J., André, Marc, Lybeert, Marnix L.M., Stamatoullas, Aspasia, Beijert, Max, Hélias, Philippe, Eghbali, Houchingue, Gabarre, Jean, van der Maazen, Richard W.M., Jaubert, Jérôme, Bouabdallah, Krimo, Boulat, Olivier, Roesink, Judith M., Christian, Bernard, Ong, Francisca, Bordessoule, Dominique, Tertian, Gérard, Gonzalez, Hugo, Vranovsky, Andrej, Quittet, Philippe, Tirelli, Umberto, de Jong, Daphne, Audouin, Josée, Aleman, Berthe M.P., and Henry-Amar, Michel

Published
2018
Full Text
View/download PDF

28. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial

Author

Komrokji, Rami, Garcia-Manero, Guillermo, Ades, Lionel, Prebet, Thomas, Steensma, David P, Jurcic, Joseph G, Sekeres, Mikkael A, Berdeja, Jesus, Savona, Michael R, Beyne-Rauzy, Odile, Stamatoullas, Aspasia, DeZern, Amy E, Delaunay, Jacques, Borthakur, Gautam, Rifkin, Robert, Boyd, Thomas E, Laadem, Abderrhamane, Vo, Bond, Zhang, Jennie, Puccio-Pick, Marie, Attie, Kenneth M, Fenaux, Pierre, and List, Alan F

Published
2018
Full Text
View/download PDF

29. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH)

Author

Fornecker, Luc-Matthieu, Lazarovici, Julien, Aurer, Igor, Casasnovas, René-Olivier, Gac, Anne-Claire, Bonnet, Christophe, Bouabdallah, Krimo, Feugier, Pierre, Specht, Lena, Molina, Lysiane, Touati, Mohamed, Borel, Cécile, Stamatoullas, Aspasia, Nicolas-Virelizier, Emmanuelle, Pascal, Laurent, Lugtenburg, Pieternella, Di Renzo, Nicola, Vander Borght, Thierry, Traverse-Glehen, Alexandra, Dartigues, Peggy, Hutchings, Martin, Versari, Annibale, Meignan, Michel, Federico, Massimo, André, Marc, LYSA-FIL-EORTC Intergroup, Hematology, UCL - (MGD) Service d'hématologie, and UCL - SSS/IREC/MONT - Pôle Mont Godinne

Subjects
Adult, Brentuximab Vedotin, Cancer Research, Adolescent, Middle Aged, Vinblastine, Hodgkin Disease, Dacarbazine, Hodgkin lymphoma, brentuximab vedotin, Young Adult, Bleomycin, Treatment Outcome, Oncology, SDG 3 - Good Health and Well-being, Doxorubicin, Antineoplastic Combined Chemotherapy Protocols, Humans, Neoplasm Staging
Abstract

PURPOSE The prognosis of patients with early-stage unfavorable Hodgkin lymphoma remains unsatisfactory. We assessed the efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) in previously untreated, early-stage unfavorable Hodgkin lymphoma (ClinicalTrials.gov identifier: NCT02292979 ). METHODS BREACH is a multicenter, randomized, open-label, phase II trial. Eligible patients were age 18-60 years with ≥ 1 unfavorable EORTC/LYSA criterion. Patients were randomly assigned (2:1) to four cycles of BV-AVD or standard doxorubicin, bleomycin, vincristine, and dacarbazine (ABVD), followed by 30 Gy involved node radiotherapy. The primary end point was the positron emission tomography (PET) response rate after two cycles by expert independent review using the Deauville score. The study was designed to test if the PET-negative rate after two cycles of BV-AVD was superior to 75%. We hypothesized a 10% increase in the PET-negative rate after two cycles of BV-AVD. RESULTS Between March 2015 and October 2016, 170 patients were enrolled. After two cycles, the primary end point of the study was met: 93 (82.3%; 90% CI, 75.3 to 88.0) of 113 patients in the BV-AVD arm were PET-negative (Deauville score 1-3) compared with 43 (75.4%; 90% CI, 64.3% to 84.5%) of 57 in the ABVD arm. The 2-year progression-free survival (PFS) was 97.3% (95% CI, 91.9 to 99.1) and 92.6% (95% CI, 81.4% to 97.2%) in the BV-AVD and ABVD arms, respectively. High total metabolic tumor volume was associated with a significantly shorter PFS (hazard ratio, 17.9; 95% CI, 2.2 to 145.5; P < .001). For patients with high total metabolic tumor volume, the 2-year PFS rate was 90.9% (95% CI, 74.4 to 97.0) and 70.7% (95% CI, 39.4% to 87.9%) in the BV-AVD and ABVD arms, respectively. CONCLUSION BV-AVD demonstrated an improvement in the PET-negative rate compared with ABVD after two cycles.

Published
2023

30. Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study

Author

Vincent Camus, Mathieu Viennot, Justine Lequesne, Pierre-Julien Viailly, Elodie Bohers, Lucile Bessi, Bénédicte Marcq, Pascaline Etancelin, Sydney Dubois, Jean-Michel Picquenot, Elena-Liana Veresezan, Marie Cornic, Lucie Burel, Justine Loret, Stéphanie Becker, Pierre Decazes, Pascal Lenain, Stéphane Lepretre, Emilie Lemasle, Hélène Lanic, Anne-Lise Ménard, Nathalie Contentin, Hervé Tilly, Aspasia Stamatoullas, and Fabrice Jardin

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

The relevance of circulating tumor DNA (ctDNA) analysis as a liquid biopsy and minimal residual disease tool in the management of classical Hodgkin Lymphoma (cHL) patients was demonstrated in retrospective settings and remains to be confirmed in a prospective setting. We developed a targeted Next-Generation sequencing (NGS) panel for fast analysis (AmpliSeq technology) of nine commonly mutated genes in biopies and ctDNA of cHL patients. We then conducted a prospective trial to assess ctDNA follow up at diagnosis and after 2 cycles of chemotherapy (C2). Sixty cHL patients treated by first line conventional chemotherapy (BEACOPPescalated [21.3%], ABVD/ABVD-like [73.5%] and other regimens [5.2%, for elderly patients] were assessed in this non-interventional study. Median age of the patients was 33.5 years (range 20-86). Variants were identified in 42 (70%) patients. Mutations of NFKBIE, TNFAIP3, STAT6, PTPN1, B2M, XPO1, ITPKB, GNA13 and SOCS1 were found in 13.3%, 31.7%, 23.3%, 5%, 33.3%, 10%, 23.3%, 13.3% and 50% of patients, respectively. ctDNA concentration and genotype are correlated with clinical characteristics and presentation. Regarding early therapeutic response, 45 patients (83%, NA=6) had a negative positron emission tomography (PET) after C2 (Deauville Score 1-3). Mean of DeltaSUVmax after C2 was -78.8%. We analyzed ctDNA after C2 for 54 patients (90%). ctDNA became rapidly undetectable in all cases after C2. Variant detection in ctDNA is suitable to depict the genetic features of cHL at diagnosis and may help to assess early treatment response, in association with PET. Clinical Trial reference: NCT02815137.

Published
2020
Full Text
View/download PDF

31. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma

Author

Merryman, Reid W., Kim, Haesook T., Zinzani, Pier Luigi, Carlo-Stella, Carmelo, Ansell, Stephen M., Perales, Miguel-Angel, Avigdor, Abraham, Halwani, Ahmad S., Houot, Roch, Marchand, Tony, Dhedin, Nathalie, Lescaut, Willy, Thiebaut-Bertrand, Anne, François, Sylvie, Stamatoullas-Bastard, Aspasia, Rohrlich, Pierre-Simon, Labussière Wallet, Hélène, Castagna, Luca, Santoro, Armando, Bachanova, Veronika, Bresler, Scott C., Srivastava, Amitabh, Kim, Harim, Pesek, Emily, Chammas, Marie, Reynolds, Carol, Ho, Vincent T., Antin, Joseph H., Ritz, Jerome, Soiffer, Robert J., and Armand, Philippe

Published
2017
Full Text
View/download PDF

32. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

Author

Oliva, Esther N, Alati, Caterina, Santini, Valeria, Poloni, Antonella, Molteni, Alfredo, Niscola, Pasquale, Salvi, Flavia, Sanpaolo, Grazia, Balleari, Enrico, Germing, Ulrich, Fenaux, Pierre, Stamatoullas, Aspasia, Palumbo, Giuseppe A, Salutari, Prassede, Impera, Stefana, Avanzini, Paolo, Cortelezzi, Agostino, Liberati, Anna Marina, Carluccio, Paola, Buccisano, Francesco, Voso, Maria Teresa, Mancini, Stefano, Kulasekararaj, Austin, Morabito, Fortunato, Bocchia, Monica, Cufari, Patrizia, Spiriti, Maria Antonietta Aloe, Santacaterina, Irene, D'Errigo, Maria Grazia, Bova, Irene, Zini, Gina, and Latagliata, Roberto

Published
2017
Full Text
View/download PDF

34. Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy

Author

Alexandra, Zduniak, Emilie, Lévêque, Anne, Perdrix, Pascaline, Etancelin, Anne-Lise, Ménard, Pascal, Lenain, Nathalie, Contentin, Louis-Ferdinand, Pépin, Stéphane, Leprêtre, Emilie, Lemasle, Hélène, Lanic, Aspasia, Stamatoullas-Bastard, Leila, Kammoun-Quique, Hervé, Tilly, Fabrice, Bauer, Fabrice, Jardin, and Vincent, Camus

Subjects
Cancer Research, Oncology, Hematology
Abstract

We conducted a single-center retrospective study to assess cardiovascular (CV) toxicity and treatment discontinuation for CV toxicity in diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) patients treated with immunochemotherapy (R-CHOP-like). Between 2006 and 2017, 433 patients were included (DLBCL

Published
2022
Full Text
View/download PDF

35. Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study

Author

Aspasia Stamatoullas, Hervé Ghesquières, Pierre Feugier, Marc André, Fabien Le Bras, Anne-Claire Gac, Cécile Borel, Thomas Gastinne, Philippe Quittet, Franck Morschhauser, Vincent Ribrag, Stephanie Guidez, Emmanuelle Nicolas-Virelizier, Alina Berriolo-Riedinger, Thierry Vander Borght, Véronique Edeline, Pauline Brice, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), and Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)

Subjects
relapse, refractory, Cancer Research, autologous stem cell transplantation, Oncology, brentuximab vedotin, [SDV]Life Sciences [q-bio], salvage chemotherapy, ICE regimen, Hematology, Hodgkin lymphoma
Abstract

This phase I/II study assessed the combination of brentuximab vedotin (BV) with ifosfamide-carboplatin-etoposide (ICE) as a second-line therapy in refractory/relapsed (R/R) classical Hodgkin lymphoma (cHL) patients. Phase I study was designed to determine the maximum tolerated dose (MTD) of BV (10 patients) and phase II evaluated the rate of complete metabolic response (CMR) after 2 cycles of BV-ICE (42 patients). There were no dose-limiting toxicities (DLT) during phase I recommending BV 1.8 mg/kg for phase II. Twenty-six patients (61.9%) achieved CMR after 2 cycles of BV-ICE and 37 patients (88%) were transplanted. With a median follow-up of 38 months, the 3-year progression free survival (PFS) and overall survival (OS) rate were 64.3% and 100%, respectively. Hematological toxicities (81%) and infections (21%) were the most frequent adverse event encountered BV-ICE regimen is feasible with manageable toxicities and could be an alternative to other salvage treatments. : ClinicalTrials.gov identifier: NCT02686346.

Published
2022
Full Text
View/download PDF

36. Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T-cell lymphoma: a case report

Author

Camus, Vincent, primary, Etancelin, Pascaline, additional, Drieux, Fanny, additional, Veresezan, Elena-Liana, additional, PICQUENOT, Jean-MIchel, additional, Penther, Dominique, additional, Viennot, Mathieu, additional, Ruminy, Philippe, additional, Contentin, Nathalie, additional, Lemasle, Emilie, additional, lepretre, stephane, additional, Dubois, Sydney, additional, Penichoux, Juliette, additional, Stamatoullas, Aspasia, additional, Zduniak, Alexandra, additional, Lanic, Helene, additional, and Jardin, Fabrice, additional

Published
2023
Full Text
View/download PDF

37. Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B-cell lymphoma: results of a multicentric prospective cohort study

Author

Juliette, Pénichoux, primary, Hélène, Lanic, additional, Caroline, Thill, additional, Anne-Lise, Ménard, additional, Vincent, Camus, additional, Aspasia, Stamatoullas, additional, Emilie, Lemasle, additional, Stéphane, Leprêtre, additional, Pascal, Lenain, additional, Nathalie, Contentin, additional, Jerôme, Kraut-Tauzia, additional, Christophe, Fruchart, additional, Leila, Kammoun, additional, Gandhi, Damaj, additional, Agathe, Farge, additional, Caroline, Delette, additional, Romain, Modzelewski, additional, Sandrine, Vaudaux, additional, Louis-Ferdinand, Pépin, additional, Hervé, Tilly, additional, and Fabrice, Jardin, additional

Published
2023
Full Text
View/download PDF

38. Work and education interruption in long-term Hodgkin lymphoma survivors: an analysis among patients from nine EORTC-LYSA trials

Author

Juul, Sidsel J., primary, Rossetti, Sára, additional, Kicinski, Michal, additional, van der Kaaij, Marleen A. E., additional, Giusti, Francesco, additional, Meijnders, Paul, additional, Aleman, Berthe M. P., additional, Raemaekers, John M. M., additional, Kluin-Nelemans, Hanneke C., additional, Spina, Michele, additional, Fermé, Christophe, additional, Renaud, Loïc, additional, Casasnovas, Olivier, additional, Stamatoullas, Aspasia, additional, André, Marc, additional, Le Bras, Fabien, additional, Plattel, Wouter J., additional, Henry-Amar, Michel, additional, Hutchings, Martin, additional, and Maraldo, Maja V., additional

Published
2023
Full Text
View/download PDF

39. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH):A Multicenter, Open-Label, Randomized, Phase II Trial

Author

Fornecker, Luc Matthieu, Lazarovici, Julien, Aurer, Igor, Casasnovas, René Olivier, Gac, Anne Claire, Bonnet, Christophe, Bouabdallah, Krimo, Feugier, Pierre, Specht, Lena, Molina, Lysiane, Touati, Mohamed, Borel, Cécile, Stamatoullas, Aspasia, Nicolas-Virelizier, Emmanuelle, Pascal, Laurent, Lugtenburg, Pieternella, Di Renzo, Nicola, Vander Borght, Thierry, Traverse-Glehen, Alexandra, Dartigues, Peggy, Hutchings, Martin, Versari, Annibale, Meignan, Michel, Federico, Massimo, André, Marc, Fornecker, Luc Matthieu, Lazarovici, Julien, Aurer, Igor, Casasnovas, René Olivier, Gac, Anne Claire, Bonnet, Christophe, Bouabdallah, Krimo, Feugier, Pierre, Specht, Lena, Molina, Lysiane, Touati, Mohamed, Borel, Cécile, Stamatoullas, Aspasia, Nicolas-Virelizier, Emmanuelle, Pascal, Laurent, Lugtenburg, Pieternella, Di Renzo, Nicola, Vander Borght, Thierry, Traverse-Glehen, Alexandra, Dartigues, Peggy, Hutchings, Martin, Versari, Annibale, Meignan, Michel, Federico, Massimo, and André, Marc

Abstract

PURPOSE The prognosis of patients with early-stage unfavorable Hodgkin lymphoma remains unsatisfactory. We assessed the efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) in previously untreated, early-stage unfavorable Hodgkin lymphoma (ClinicalTrials.gov identifier: NCT02292979). METHODS BREACH is a multicenter, randomized, open-label, phase II trial. Eligible patients were age 18-60 years with ≥ 1 unfavorable EORTC/LYSA criterion. Patients were randomly assigned (2:1) to four cycles of BV-AVD or standard doxorubicin, bleomycin, vincristine, and dacarbazine (ABVD), followed by 30 Gy involved node radiotherapy. The primary end point was the positron emission tomography (PET) response rate after two cycles by expert independent review using the Deauville score. The study was designed to test if the PET-negative rate after two cycles of BV-AVD was superior to 75%. We hypothesized a 10% increase in the PET-negative rate after two cycles of BV-AVD. RESULTS Between March 2015 and October 2016, 170 patients were enrolled. After two cycles, the primary end point of the study was met: 93 (82.3%; 90% CI, 75.3 to 88.0) of 113 patients in the BV-AVD arm were PET-negative (Deauville score 1-3) compared with 43 (75.4%; 90% CI, 64.3% to 84.5%) of 57 in the ABVD arm. The 2-year progression-free survival (PFS) was 97.3% (95% CI, 91.9 to 99.1) and 92.6% (95% CI, 81.4% to 97.2%) in the BV-AVD and ABVD arms, respectively. High total metabolic tumor volume was associated with a significantly shorter PFS (hazard ratio, 17.9; 95% CI, 2.2 to 145.5; P < .001). For patients with high total metabolic tumor volume, the 2-year PFS rate was 90.9% (95% CI, 74.4 to 97.0) and 70.7% (95% CI, 39.4% to 87.9%) in the BV-AVD and ABVD arms, respectively. CONCLUSION BV-AVD demonstrated an improvement in the PET-negative rate compared with ABVD after two cycles., PURPOSEThe prognosis of patients with early-stage unfavorable Hodgkin lymphoma remains unsatisfactory. We assessed the efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) in previously untreated, early-stage unfavorable Hodgkin lymphoma (ClinicalTrials.gov identifier: NCT02292979).METHODSBREACH is a multicenter, randomized, open-label, phase II trial. Eligible patients were age 18-60 years with ≥ 1 unfavorable EORTC/LYSA criterion. Patients were randomly assigned (2:1) to four cycles of BV-AVD or standard doxorubicin, bleomycin, vincristine, and dacarbazine (ABVD), followed by 30 Gy involved node radiotherapy. The primary end point was the positron emission tomography (PET) response rate after two cycles by expert independent review using the Deauville score. The study was designed to test if the PET-negative rate after two cycles of BV-AVD was superior to 75%. We hypothesized a 10% increase in the PET-negative rate after two cycles of BV-AVD.RESULTSBetween March 2015 and October 2016, 170 patients were enrolled. After two cycles, the primary end point of the study was met: 93 (82.3%; 90% CI, 75.3 to 88.0) of 113 patients in the BV-AVD arm were PET-negative (Deauville score 1-3) compared with 43 (75.4%; 90% CI, 64.3% to 84.5%) of 57 in the ABVD arm. The 2-year progression-free survival (PFS) was 97.3% (95% CI, 91.9 to 99.1) and 92.6% (95% CI, 81.4% to 97.2%) in the BV-AVD and ABVD arms, respectively. High total metabolic tumor volume was associated with a significantly shorter PFS (hazard ratio, 17.9; 95% CI, 2.2 to 145.5; P <.001). For patients with high total metabolic tumor volume, the 2-year PFS rate was 90.9% (95% CI, 74.4 to 97.0) and 70.7% (95% CI, 39.4% to 87.9%) in the BV-AVD and ABVD arms, respectively.CONCLUSIONBV-AVD demonstrated an improvement in the PET-negative rate compared with ABVD after two cycles.

Published
2023

40. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

Author

Marie Sébert, Aline Renneville, Cécile Bally, Pierre Peterlin, Odile Beyne-Rauzy, Laurence Legros, Marie-Pierre Gourin, Laurence Sanhes, Eric Wattel, Emmanuel Gyan, Sophie Park, Aspasia Stamatoullas, Anne Banos, Kamel Laribi, Simone Jueliger, Luke Bevan, Fatiha Chermat, Rosa Sapena, Olivier Nibourel, Cendrine Chaffaut, Sylvie Chevret, Claude Preudhomme, Lionel Adès, and Pierre Fenaux

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

High-risk myelodysplastic syndrome/acute myeloid leukemia patients have a very poor survival after azacitidine failure. Guadecitabine (SGI-110) is a novel subcutaneous hypomethylating agent which results in extended decitabine exposure. This multicenter phase II study evaluated the efficacy and safety of guadecitabine in high-risk myelodysplastic syndrome and low blast count acute myeloid leukemia patients refractory or relapsing after azacitidine. We included 56 patients with a median age of 75 years [Interquartile Range (IQR) 69-76]. Fifty-five patients received at least one cycle of guadecitabine (60 mg/m2/d subcutaneously days 1-5 per 28-day treatment cycles), with a median of 3 cycles (range, 0-27). Eight (14.3%) patients responded, including two complete responses; median response duration was 11.5 months. Having no or few identified somatic mutations was the only factor predicting response (P=0.035). None of the 11 patients with TP53 mutation responded. Median overall survival was 7.1 months, and 17.9 months in responders (3 of whom had overall survival >2 years). In multivariate analysis, IPSS-R (revised International Prognostic Scoring System) score other than very high (P=0.03) primary versus secondary azacitidine failure (P=0.01) and a high rate of demethylation in blood during the first cycle of treatment (P=0.03) were associated with longer survival. Thus, guadecitabine can be effective, sometimes yielding relatively prolonged survival, in a small proportion of high-risk myelodysplastic syndrome/low blast count acute myeloid leukemia patients who failed azacitidine. (Trial registered at clinicaltrials.gov identifier: 02197676)

Published
2019
Full Text
View/download PDF

41. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

Author

Chesnais, Virginie, Renneville, Aline, Toma, Andrea, Lambert, Jérôme, Passet, Marie, Dumont, Florent, Chevret, Sylvie, Lejeune, Julie, Raimbault, Anna, Stamatoullas, Aspasia, Rose, Christian, Beyne-Rauzy, Odile, Delaunay, Jacques, Solary, Eric, Fenaux, Pierre, Dreyfus, François, Preudhomme, Claude, Kosmider, Olivier, and Fontenay, Michaela

Published
2016
Full Text
View/download PDF

42. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)

Author

Oliva, Esther Natalie, Riva, Marta, Niscola, Pasquale, Santini, Valeria, Breccia, Massimo, Giai, Valentina, Poloni, Antonella, Patriarca, Andrea, Crisà, Elena, Capodanno, Isabella, Salutari, Prassede, Reda, Gianluigi, Cascavilla, Nicola, Ferrero, Dario, Guarini, Attilio, Tripepi, Giovanni, Iannì, Giuseppe, Russo, Emilio, Castelli, Andrea, Fattizzo, Bruno, Beltrami, Germana, Bocchia, Monica, Molteni, Alfredo, Fenaux, Pierre, Germing, Ulrich, Ricco, Alessandra, Palumbo, Giuseppe A, Impera, Stefana, Di Renzo, Nicola, Rivellini, Flavia, Buccisano, Francesco, Stamatoullas-Bastard, Aspasia, Liberati, Anna Marina, Candoni, Anna, Delfino, Ilaria Maria, Arcadi, Maria Teresa, Cufari, Patrizia, Rizzo, Lorenzo, Bova, Irene, D'Errigo, Maria Grazia, Zini, Gina, and Latagliata, Roberto

Subjects
Settore MED/15
Published
2023

43. Red blood cell transfusion burden in myelodysplastic syndromes ( <scp>MDS</scp> ) with ring Sideroblasts ( <scp>RS</scp> ): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies ( <scp>GFM</scp> )

Author

Claire Jouzier, Amina Cherait, Pascale Cony‐Makhoul, Jean‐François Hamel, Melanie Veloso, Sylvain Thepot, Thomas Cluzeau, Aspasia Stamatoullas, Alice Garnier, Agnès Guerci‐Bresler, Sophie Dimicoli‐Salazar, Gian Matteo Pica, Stéphane Cheze, Clémence Santana, Fatiha Chermat, Pierre Fenaux, and Sophie Park

Subjects
Myelodysplastic Syndromes, Immunology, Humans, Immunology and Allergy, Anemia, Hematology, Erythrocyte Transfusion, Iron Chelating Agents, Retrospective Studies
Abstract

MDS-RS patients are characterized by chronic anemia and a low risk of Acute Myeloid Leukemia (AML) progression and they generally become Red Blood Cell (RBC) transfusion dependent (TD).We performed a retrospective "real-life" observational study of 6 months in 100 MDS-RS TD patients, recruited in 12 French centers, to describe transfusion characteristics, and evaluate the frequency and causes of hospitalizations, health costs, and morbidity, associated with transfusion dependency, in a French population of RBC transfusion-dependent MDS-RS patients.79% of the patients had high transfusion burden (HTB) and 21% low transfusion burden (LTB). HTB patients had a longer disease duration (6 vs. 3.7 years, p = 0.0078), more frequent iron chelation (82% vs. 50%, p = 0.0052) and higher serum ferritin (p = 0.03). During the 6-month study period, 22% of the patients required inpatient hospitalization, 36% of them for symptomatic anemia requiring emergency RBC transfusion. The 6-month median transfusion costs, including the cost of the day care facility, transportation to and from the hospital, iron chelation, and lab tests, was 16,188€/patient.MDS-RS represents the archetypal type of chronically transfused lower-risk MDS. Most of those patients have a high transfusion burden and thus frequently need visits to the hospital's day care facility, and frequent hospitalizations, with an overall high median treatment cost. Those costs should be compared with costs of new treatments potentially able to avoid RBC transfusion dependence and to reduce the complications of chronic anemia in MDS-RS patients.

Published
2022
Full Text
View/download PDF

44. A randomised phase <scp>II</scp> study of azacitidine ( <scp>AZA</scp> ) alone or with Lenalidomide ( <scp>LEN</scp> ), Valproic acid ( <scp>VPA</scp> ) or Idarubicin ( <scp>IDA</scp> ) in <scp>higher‐Risk MDS</scp> or low blast <scp>AML</scp> : <scp>GFM</scp> 's 'pick a winner' trial, with the impact of somatic mutations

Author

Lionel Adès, Nicolas Duployez, Agnes Guerci‐Bresler, Kamel Laribi, Pierre Peterlin, Norbert Vey, Sylvain Thepot, Stefan Wickenhauser, Hacene Zerazhi, Aspassia Stamatoullas, Eric Wattel, Christian Recher, Andrea Toma, Sophie Dimicoli‐Salazar, Thorsten Braun, Odile Beyne‐Rauzy, Jean‐Pierre Marolleau, Stéphane Cheze, Sophie Park, Thomas Cluzeau, Stanislas Nimubona, Dominique Bordessoule, Riad Benramdane, Bruno Quesnel, Shanti Amé, Stéphane de Botton, Fathia Chermat, Claude Preudhomme, Sylvie Chevret, and Pierre Fenaux

Subjects
Hematology
Published
2022
Full Text
View/download PDF

45. Positron Emission Tomography–Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study

Author

René-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, Julien Lazarovici, Hervé Ghesquieres, Aspasia Stamatoullas, Jehan Dupuis, Anne-Claire Gac, Thomas Gastinne, Bertrand Joly, Krimo Bouabdallah, Emmanuelle Nicolas-Virelizier, Pierre Feugier, Franck Morschhauser, David Sibon, Christophe Bonnet, Alina Berriolo-Riedinger, Véronique Edeline, Marie Parrens, Diane Damotte, Diane Coso, Marc André, Michel Meignan, Cédric Rossi, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service d'hématologie

Subjects
Adult, Cancer Research, Adolescent, Neoplasms, Second Primary, Middle Aged, Vinblastine, Hodgkin Disease, Dacarbazine, Bleomycin, Young Adult, Oncology, Doxorubicin, Vincristine, Positron-Emission Tomography, Procarbazine, Antineoplastic Combined Chemotherapy Protocols, Humans, Prednisone, Cyclophosphamide, Etoposide, Follow-Up Studies, Neoplasm Staging
Abstract

PURPOSE The AHL2011 study (ClinicalTrials.gov identifier: NCT01358747 ) demonstrated that a positron emission tomography (PET)-driven de-escalation strategy after two cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) provides similar progression-free survival (PFS) and overall survival (OS) and reduces early toxicity compared with a nonmonitored standard treatment. Here, we report, with a prolonged follow-up, the final study results. METHODS Patients with advanced Hodgkin lymphoma (stage III, IV, or IIB with mediastinum/thorax ratio > 0.33 or extranodal involvement) age 16-60 years were prospectively randomly assigned between 6 × BEACOPP and a PET-driven arm after 2 × BEACOPP delivering 4 × ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) in PET2– and 4 × BEACOPP in PET2+ patients. PET performed after four cycles of chemotherapy had to be negative to complete the planned treatment. RESULTS In total, 823 patients were enrolled including 413 in the standard arm and 410 in the PET-driven arm. With a 67.2-month median follow-up, 5-year PFS (87.5% v 86.7%; hazard ratio [HR] = 1.07; 95% CI, 0.74 to 1.57; P = .67) and OS (97.7% in both arms; HR = 1.012; 95% CI, 0.50 to 2.10; P = .53) were similar in both randomization arms. In the whole cohort, full interim PET assessment predicted patients' 5-year PFS (92.3% in PET2–/PET4–, 75.4% [HR = 3.26; 95% CI, 18.3 to 5.77] in PET2+/PET4– and 46.5% [HR = 12.4; 95% CI, 7.31 to 19.51] in PET4+ patients, respectively; P < .0001) independent of international prognosis score. Five-year OS was also affected by interim PET results, and PET2+/PET4– patients (93.5%; HR = 3.3; 95% CI, 1.07 to 10.1; P = .036) and PET4+ patients (91.9%; HR = 3.756; 95% CI, 1.07 to 13.18; P = .038) had a significant lower OS than PET2–/PET4– patients (98.2%). Twenty-two patients (2.7%) developed a second primary malignancy, 13 (3.2%) and 9 (2.2%) in the standard and experimental arms, respectively. CONCLUSION The extended follow-up confirms the continued efficacy and favorable safety of AHL2011 PET-driven strategy, which is noninferior to standard six cycles of BEACOPP. PET4 provides additional prognostic information to PET2 and allows identifying patients with particularly poor prognosis.

Published
2022
Full Text
View/download PDF

46. Azacitidine for the treatment of relapsed and refractory AML in older patients

Author

Itzykson, Raphael, Thépot, Sylvain, Berthon, Céline, Delaunay, Jacques, Bouscary, Didier, Cluzeau, Thomas, Turlure, Pascal, Prébet, Thomas, Dartigeas, Caroline, Marolleau, Jean-Pierre, Recher, Christian, Plantier, Isabelle, Stamatoullas, Aspasia, Devidas, Alain, Taksin, Anne-Laure, Guièze, Romain, Caillot, Denis, Vey, Norbert, Adès, Lionel, Ifrah, Norbert, Dombret, Hervé, Fenaux, Pierre, and Gardin, Claude

Published
2015
Full Text
View/download PDF

47. Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study

Author

Vincent, Camus, Mathieu, Viennot, Emilie, Lévêque, Pierre-Julien, Viailly, David, Tonnelet, Elena-Liana, Veresezan, Fanny, Drieux, Pascaline, Etancelin, Sydney, Dubois, Aspasia, Stamatoullas, Hervé, Tilly, Elodie, Bohers, and Fabrice, Jardin

Subjects
Adult, Cancer Research, Lymphoma, B-Cell, Oncology, Humans, Lymphoma, Large B-Cell, Diffuse, Hematology, Hodgkin Disease, Mediastinal Neoplasms, Circulating Tumor DNA, Retrospective Studies
Abstract

Few data exist concerning circulating tumor DNA (ctDNA) relevance in primary mediastinal B-cell lymphoma (PMBL). To explore this topic, we applied a 9-gene next-generation sequencing pipeline to samples from forty-four PMBL patients (median age 36.5 years). The primary endpoint was a similarity between paired biopsy/plasma mutational profiles. We detected at least one variant in 32 plasma samples (80%). The similarity between the biopsy and ctDNA genetic profiles for the 30 patients with paired mutated biopsy/plasma samples was greater than or equal to 80% in 19 patients (63.3%). We then compared PMBL ctDNA features with those of a cohort of Hodgkin lymphoma patients (

Published
2022
Full Text
View/download PDF

48. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable – a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Author

Joanna Drozd-Sokolowska, Luuk Gras, Nienke Zinger, Mohsen Al Zahrani, Jakob Passweg, Jenny Byrne, Aloysius Ho, Xiao-jun Huang, Nicolaus Kröger, Jiri Mayer, Domenico Russo, Ann De Becker, Abdelghani Tbakhi, Aspasia Stamatoullas, Thomas Valerius, Patrick Hayden, Donal P. McLornan, Francesco Onida, Christof Scheid, Marie Robin, Ibrahim Yakoub-Agha, Hematology, and Faculty of Medicine and Pharmacy

Subjects
Transplantation, myelodysplastic syndrome unclassifiable, Hematology, Allogeneic hematopoietic cell transplantation
Published
2023
Full Text
View/download PDF

49. Work and education interruption in long-term Hodgkin lymphoma survivors : an analysis among patients from nine EORTC-LYSA trials

Author

Sidsel J. Juul, Sára Rossetti, Michal Kicinski, Marleen A. E. van der Kaaij, Francesco Giusti, Paul Meijnders, Berthe M. P. Aleman, John M. M. Raemaekers, Hanneke C. Kluin-Nelemans, Michele Spina, Christophe Fermé, Loïc Renaud, Olivier Casasnovas, Aspasia Stamatoullas, Marc André, Fabien Le Bras, Wouter J. Plattel, Michel Henry-Amar, Martin Hutchings, Maja V. Maraldo, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service d'hématologie

Subjects
education, work, Oncology, employment, Radiology, Nuclear Medicine and imaging, Hematology, General Medicine, Human medicine, survivorship, Hodgkin lymphoma
Abstract

Background: Disease-specific studies on the impact of Hodgkin lymphoma (HL) on education or work interruption and resumption are lacking. Material and methods: In a cross-sectional study conducted among long-term HL survivors enrolled from 1964 to 2004 in nine randomised EORTC-LYSA trials, the interruption and resumption of education/work was investigated. Survivors alive 5-44 years after diagnosis who were studying or working at time of diagnosis were included (n = 1646). Patient and treatment characteristics were obtained from trial records. Education and work outcomes were collected using the Life Situation Questionnaire. Logistic regression was used to model education or work interruption; Cox regression was used to study resumption rates. Results: Among survivors studying at time of diagnosis (n = 323), 52% (95% CI: 46-57%) interrupted their education; however, it was resumed within 24 months by 92% (95% CI: 87-96%). The probability of interruption decreased with time: the more recent the treatment era, the lower the risk (OR 0.70 per 10 years, 95% CI: 0.49-1.01). Treatment with radiotherapy (yes vs. no) was associated with a higher education resumption rate (HR 2.01, 95% CI 1.07-3.78) whereas age, sex, stage, radiotherapy field and chemotherapy were not.Among survivors working at time of diagnosis (n = 1323), 77% (95% CI: 75-79%) interrupted their work. However, it was resumed within 24 months by 86% (95% CI: 84%-88%). Women were more likely to interrupt their work as compared to men (OR 1.90, 95% CI: 1.44-2.51) and, when interrupted, less likely to resume work (HR 0.70, 95% CI: 0.61-0.80). Survivors with a higher educational level were less likely to interrupt their work (OR 0.68 for university vs. no high school, 95% CI: 0.46-1.03); and when interrupted, more likely to resume work (HR 1.50 for university vs. no high school, 95% CI: 1.21-1.86). Increasing age was also associated with lower resumption rates (HR 0.62 for age ≥50 vs. 18-29 years, 95% CI: 0.41-0.94). Conclusion: An interruption in education/work was common among long-term HL survivors. However, most of the survivors who interrupted their studies or work had resumed their activities within 24 months. In this study, no associations between survivors' characteristics and failure to resume education were observed. Female sex, age ≥50 years, and a lower level of education were found to be associated with not resuming work after treatment for HL.

Published
2023

50. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma

Author

Eric Van Den Neste, Marc André, Thomas Gastinne, Aspasia Stamatoullas, Corinne Haioun, Amine Belhabri, Oumedaly Reman, Olivier Casasnovas, Hervé Ghesquieres, Gregor Verhoef, Marie-José Claessen, Hélène A. Poirel, Marie-Christine Copin, Romain Dubois, Peter Vandenberghe, Ioanna-Andrea Stoian, Anne S. Cottereau, Sarah Bailly, Laurent Knoops, and Franck Morschhauser

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

JAK2 constitutive activation/overexpression is common in classical Hodgkin lymphoma, and several cytokines stimulate Hodgkin lymphoma cells by recognizing JAK1-/JAK2-bound receptors. JAK blockade may thus be therapeutically beneficial in Hodgkin lymphoma. In this phase II study we assessed the safety and efficacy of ruxolitinib, an oral JAK1/2 inhibitor, in patients with relapsed/refractory Hodgkin lymphoma. The primary objective was overall response rate according to the International Harmonization Project 2007 criteria. Thirty-three patients with advanced disease (median number of prior lines of treatment: 5; refractory: 82%) were included; nine (27.3%) received at least six cycles of ruxolitinib and six (18.2%) received more than six cycles. The overall response rate after six cycles was 9.4% (3/32 patients). All three responders had partial responses; another 11 patients had transient stable disease. Best overall response rate was 18.8% (6/32 patients). Rapid alleviation of B-symptoms was common. The median duration of response was 7.7 months, median progression-free survival 3.5 months (95% CI: 1.9–4.6), and the median overall survival 27.1 months (95% CI: 14.4–27.1). Forty adverse events were reported in 14/33 patients (42.4%). One event led to treatment discontinuation, while 87.5% of patients recovered without sequelae. Twenty-five adverse events were grade 3 or higher. These events were mostly anemia (n=11), all considered related to ruxolitinib. Other main causes of grade 3 or higher adverse events included lymphopenia and infections. Of note, no cases of grade 4 neutropenia or thrombocytopenia were observed. Ruxolitinib shows signs of activity, albeit short-lived, beyond a simple anti-inflammatory effect. Its limited toxicity suggests that it has the potential to be combined with other therapeutic modalities. ClinicalTrials.gov: NCT01877005

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results